Joseph H. Antin, MD, Dana-Farber Cancer Institute
Advertisement
Articles by Joseph H. Antin, MD, Dana-Farber Cancer Institute
Advertisement
Latest Updated Articles
Risk Factors for Graft-vs-Host DiseasePublished: June 19th 2020 | Updated:
Special Transplant SituationsPublished: June 19th 2020 | Updated:
Members of the Transplant TeamPublished: June 19th 2020 | Updated:
Timing of Referral for TransplantPublished: June 19th 2020 | Updated:
Graft-vs-Host Disease Prophylaxis Clinical TrialsPublished: June 19th 2020 | Updated:
Shifting Paradigm in Treating Acute Graft-vs-Host DiseasePublished: June 19th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5